Clintex CTi·Feb 6, 2024How CTAi fits an evolving Clinical Trials marketThe global AI in clinical trials market is estimated to be worth $ 2.04 billion in 2024 and expected to grow at compounded annual growth…A response icon1A response icon1
Clintex CTi·Jan 19, 2024ClinTex x DeSciThe scientific landscape is on the cusp of a paradigm shift. Enter Decentralised Science (DeSci), a revolutionary approach that leverages…
Clintex CTi·Jan 5, 2024ClinTex CTi and DeSci — The FutureClintex CTi and DeSci both work off the idea that scientific knowledge, including clinical trial intelligence, should be accessible.
Clintex CTi·Jul 13, 2023Australian Regulator approves MDMA for PTSD treatmentAustralia made history on July 1, 2023, when it became the first country in the world to prescribe MDMA and psilocybin for therapeutic use…A response icon1A response icon1
Clintex CTi·Jan 16, 2023How AI will drive success in Clinical TrialsIt takes up to 15 years and an average total R&D expenditure of $1.5–2 billion USD to bring a single new drug to market. About half of this…
Clintex CTi·Nov 28, 2022ClinTex 2023 RoadmapOver the past few weeks we have been meeting internally to define our strategy and goals in the runup to the new year. To this end we…
Clintex CTi·Oct 31, 2022ClinTex sign Letter of Intent with LVL HealthClintex are excited to announce the signing of an agreement with LVL Health (https://lvlhealth.co.uk/) to support their CANPAIN clinical…
Clintex CTi·Oct 7, 2022Q4–2022 at ClinTex HQThe autumnal months have begun to set in here in Europe as the crypto bear market drags on, mirroring the wider global macro economic…
Clintex CTi·Sep 7, 2022ClinTex in discussions with Celadon Pharmaceuticals and LVL HealthWe are extremely excited to announce that ClinTex are currently in active discussions with two ground breaking companies, to support…
